Adenovirus Type 4 and Type 7 Vaccine, Live, Oral, Enteric Coated Tablets for Oral Administration

The Defense Logistics Agency Troop Support is seeking qualified sources capable of supplying a live, bivalent Adenovirus vaccine formulated as enteric-coated tablets for oral administration, targeting prevention of respiratory infections caused by Adenovirus types 4 and 7. The vaccine will be packaged in units containing two bottles of 100 tablets each, with one dose comprising two tablets—one of each type—totaling 200 doses per package. The contract, anticipated to be an Indefinite Delivery-Indefinite Quantity (IDIQ), will have a one-year base period with four optional one-year extensions, with estimated annual orders of approximately 2,000 packages, though actual quantities may vary significantly based on military needs. The successful vendor must have FDA approval for the vaccine prior to award, and delivery will be scheduled monthly to various military locations across the United States, beginning 3 to 6 months after contract award. This request for information aims to gather data from manufacturers, distributors, and developers of the Adenovirus vaccine or related technologies to inform procurement strategies. Respondents should provide details on manufacturing capacity, FDA registration, product features, pricing, inventory, storage, delivery timelines, and surge capacity, along with information on distribution channels and development status if applicable. The government emphasizes confidentiality and will retain all submitted information, which may also be protected under the Critical Infrastructure Information Act. Responses are voluntary and should be submitted electronically by March 7, 2025, to the designated contracting officer. This RFI does not constitute a solicitation or guarantee future procurement actions but serves to facilitate planning for potential vaccine acquisition needs.